| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.05 | 0.8 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |